Study guide
15.5 Common Dermatologic Disorders in Women Across the Lifespan
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
15.5 Common Dermatologic Disorders in Women Across the Lifespan
Key Takeaways Explain This Topic AI
Adult female acne vulgaris characteristically presents with inflammatory papules, pustules, and deep painful nodules along the lower face, jawline, chin, and neck with premenstrual exacerbations, driven by follicular hyperkeratinization, Cutibacterium acnes colonization, and androgen sensitivity.
Stepwise pharmacotherapy includes topical retinoids and benzoyl peroxide, combined oral contraceptives, oral spironolactone (50–100 mg daily; requires potassium monitoring and effective contraception to prevent feminization of male fetus), and oral isotretinoin (strictly teratogenic, requiring iPLEDGE registry compliance with two negative pregnancy tests and two concurrent contraceptive methods).
Rosacea is distinguished from acne by the absence of comedones, featuring central facial erythema, telangiectasias, and inflammatory papules triggered by UV light, alcohol, and spicy foods; managed with trigger avoidance, broad-spectrum sunscreen, topical metronidazole, ivermectin, or azelaic acid.
Specific dermatoses of pregnancy require precise differentiation: Pruritic Urticarial Papules and Plaques of Pregnancy (PUPPP) arises in abdominal striae with periumbilical sparing in late third-trimester primigravidas and carries no fetal risk, whereas Intrahepatic Cholestasis of Pregnancy (ICP) presents with severe nocturnal pruritus on palms and soles without primary rash, elevated total bile acids (≥10 µmol/L), and severe risks of sudden intrauterine demise and preterm birth.
Melanoma is a leading malignancy in reproductive-age and pregnant women; screening utilizes the ABCDE criteria (Asymmetry, Border, Color, Diameter >6 mm, Evolving), and any clinically suspicious pigmented lesion requires urgent full-thickness excisional biopsy (not superficial shave) for accurate Breslow depth staging.
Last updated: October 2026
Acne Vulgaris in Adult Women: Pathogenesis & Presentation
Acne vulgaris affects over 30% to 50% of women in their 20s and 30s. Four pathogenic factors drive lesion development:
Follicular Hyperkeratinization: Abnormal desquamation of ductal keratinocytes within the pilosebaceous infundibulum creates the microscopic precursor of all acne lesions—the microcomedone .
Androgen-Driven Sebum Production: Androgens stimulate sebocyte hypertrophy and excess sebum secretion.
Cutibacterium acnes Proliferation: Cutibacterium acnes proliferates within the lipid-rich microenvironment of plugged follicles.
Inflammatory Cascades: C. acnes hydrolyzes sebum triglycerides into free fatty acids and activates Toll-like receptor 2 (TLR2), triggering neutrophil chemotaxis and follicular rupture.
Adult Female Phenotype (The "U-Zone" Pattern)
Distribution: Concentrated along the lower third of the face , mandibular jawline, chin, and anterior neck (the "U-zone").
Morphology: Deep-seated, tender inflammatory papules, pustules, and nodulocystic lesions, often with sparse superficial comedones.
Premenstrual Flares: Over 70% of women experience flares 7 to 10 days prior to menses , coinciding with the luteal drop in estrogen relative to androgens.
Hyperandrogenism Screening: Adult-onset or treatment-resistant acne warrants evaluation for Polycystic Ovary Syndrome (PCOS), congenital adrenal hyperplasia, or adrenal/ovarian tumors if accompanied by hirsutism (Ferriman-Gallwey score >8), oligomenorrhea, androgenic alopecia, or acanthosis nigricans.
- Stepwise Pharmacotherapy: Topical Retinoids, Spironolactone & Isotretinoin iPLEDGE
- 1. Topical Regimens
Topical Retinoids (Tretinoin 0.025%–0.1%, Adapalene 0.1%–0.3%, Tazarotene): Foundational first-line therapy; normalizes follicular desquamation and prevents microcomedones. Apply a pea-sized amount at bedtime. Adverse effects: erythema, peeling, photosensitivity. Strictly contraindicated in pregnancy .
Benzoyl Peroxide (BPO 2.5%–5%): Bactericidal via reactive oxygen species; zero bacterial resistance develops. Co-prescribe with topical clindamycin to prevent antibiotic resistance.
Topical Clindamycin (1%): Anti-inflammatory antibiotic; always combine with BPO.
Topical Azelaic Acid (15%–20%): Comedolytic, antimicrobial, and inhibits tyrosinase (reduces post-inflammatory hyperpigmentation); pregnancy-safe (Category B).
Topical Dapsone (5%–7.5%): Anti-inflammatory sulfone effective for female inflammatory acne.
2. Systemic Hormonal Therapies
Combined Oral Contraceptives (COCs): FDA-approved formulations contain ethinyl estradiol with norgestimate, norethindrone acetate, or drospirenone. Estrogen increases Sex Hormone-Binding Globulin (SHBG) , reducing bioavailable free testosterone, while progestins suppress ovarian androgen production.
Oral Spironolactone (50 to 100 mg daily, titrated to 200 mg): Synthetic aldosterone antagonist and competitive androgen receptor blocker that inhibits 5-alpha reductase.
Safety & Monitoring: Baseline potassium; monitor periodically in women >45 years or those on concurrent RAAS inhibitors.
Adverse Effects: Diuresis, breast tenderness, lightheadedness, and menstrual spotting.
Teratogenicity: Risk of feminization of the male fetus (hypospadias, cryptorchidism) through antiandrogenic actions. Women of childbearing potential must use reliable contraception .
3. Oral Isotretinoin & the iPLEDGE REMS Program
Oral isotretinoin is indicated for severe recalcitrant nodulocystic acne, shrinking sebaceous glands by ~90%.
Important
Isotretinoin Teratogenicity & iPLEDGE: Isotretinoin is a potent teratogen carrying a ~30% risk of major congenital anomalies ( isotretinoin embryopathy : craniofacial dysmorphism, microtia, cleft palate, thymic aplasia, conotruncal heart defects, hydrocephalus) and a 40% spontaneous abortion rate.
Prescribing requires strict federal iPLEDGE REMS compliance:
Two negative CLIA-certified pregnancy tests prior to starting therapy (the second during the first 5 days of menses).
Documented use of two concurrent, effective forms of contraception (or continuous abstinence) starting 1 month before, during, and for 1 month post-therapy.
Monthly negative CLIA pregnancy tests prior to each 30-day prescription dispense.
Rosacea: Subtypes, Comedone Distinction & Management
Rosacea is a chronic facial inflammatory disorder affecting fair-skinned females (Fitzpatrick types I–II) aged 30 to 50.
Subtypes: Erythematotelangiectatic (flushing, persistent central erythema, telangiectasias), papulopustular (erythema with inflammatory papules/pustules), phymatous (tissue hypertrophy/rhinophyma), and ocular rosacea (blepharitis, conjunctivitis).
Diagnostic Distinction: The Comedone Rule: The critical clinical feature distinguishing rosacea from acne vulgaris is the ABSENCE OF COMEDONES . The presence of open (blackheads) or closed (whiteheads) comedones confirms acne; rosacea has no comedones.
Triggers: Ultraviolet radiation, hot beverages, spicy foods, alcohol (especially red wine), extreme temperatures, and emotional stress.
Management: Trigger avoidance, gentle skin care, daily broad-spectrum mineral sunscreen (zinc oxide/titanium dioxide). First-line topicals include metronidazole 0.75%–1% gel/cream , ivermectin 1% cream (targets Demodex folliculorum mites), and azelaic acid 15% . For severe flares, subantimicrobial-dose oral doxycycline (40 mg daily) provides anti-inflammatory matrix metalloproteinase inhibition without generating resistance.
Specific Dermatoses of Pregnancy: Differential Diagnosis & Fetal Risks
Condition Typical Onset & Parity Clinical Morphology & Distribution Fetal Morbidity Diagnostic Workup First-Line Management
PUPPP (Polymorphic Eruption of Pregnancy) Late 3rd trimester (~35 weeks); Primigravidas (75%) Intensely pruritic urticarial papules and plaques within abdominal striae ; STRIKING PERIUMBILICAL SPARING ; spreads to thighs. NONE (benign for mother and fetus). Clinical diagnosis; normal bile acids and transaminases. Topical corticosteroids (triamcinolone 0.1%), cool compresses, oral antihistamines (cetirizine).
Intrahepatic Cholestasis of Pregnancy (ICP) Late 2nd or 3rd trimester ; Multiparous predilection Severe nocturnal pruritus WITHOUT primary rash ; secondary excoriations; INVOLVES PALMS AND SOLES . HIGH: Sudden Intrauterine Fetal Demise (IUFD) , meconium aspiration, preterm birth. Total Serum Bile Acids (TBA ≥10 µmol/L) ; elevated ALT/AST in 60%–80%. Ursodeoxycholic Acid (UDCA 10–15 mg/kg/day) ; antenatal surveillance; planned delivery at 36–39 weeks .
Atopic Eruption of Pregnancy (AEP) 1st or 2nd trimester ; Any parity Eczematous lesions on flexural surfaces (neck, antecubital fossae) or prurigo papules. NONE (benign for fetus). Clinical diagnosis; elevated serum IgE; atopic history. Emollients, mild-to-moderate topical corticosteroids.
Pemphigoid Gestationis 2nd or 3rd trimester ; Multiparous predilection Autoimmune subepidermal blistering; urticarial plaques forming tense vesicles/bullae ; INVOLVES PERIUMBILICAL REGION . MODERATE: Fetal growth restriction, preterm delivery, neonatal blistering (5%–10%). Skin biopsy for Direct Immunofluorescence (DIF) : linear C3 deposition at basement membrane. High-potency topical or oral corticosteroids (prednisone 0.5–1 mg/kg/day); fetal growth scans.
Intrahepatic Cholestasis of Pregnancy (ICP) Clinical Management
Clinical Presentation: Intractable pruritus concentrated on the palms of hands and soles of feet , worsening at night, WITHOUT a primary dermatologic rash (only excoriations).
Bile Acid Stratification: Normal <10 µmol/L; Mild: 10–19 µmol/L; Moderate: 20–99 µmol/L; Severe: ≥100 µmol/L .
Fetal Hazards: Toxic bile acids induce fetal cardiomyocyte arrhythmias and placental vasoconstriction. Risk of sudden stillbirth increases exponentially when TBA ≥100 µmol/L (3% to 5% risk).
Delivery Timing (SMFM / ACOG Guidelines):
TBA ≥100 µmol/L: Deliver at 36 0/7 weeks gestation (or upon diagnosis if later).
TBA 40 to 99 µmol/L: Deliver at 36 0/7 to 39 0/7 weeks , favoring the earlier part of the window (SMFM).
TBA 10 to 39 µmol/L: Deliver at 36 0/7 to 39 0/7 weeks gestation .
Medical therapy: Ursodeoxycholic Acid (UDCA 10 to 15 mg/kg/day) lowers bile acids and relieves pruritus.
Cutaneous Melanoma Screening: ABCDE Criteria & Biopsy Standards
Cutaneous melanoma is one of the most common malignancies in reproductive-age women and during pregnancy (~8% of gestational cancers). Pregnancy does not alter stage-for-stage survival, but delays cause thicker lesions at diagnosis.
The ABCDE Screening Criteria
A - Asymmetry: One half does not match the other.
B - Border Irregularity: Notched, scalloped, or poorly circumscribed margins.
C - Color Variation: Variegated shades of brown, black, blue, red, or white.
D - Diameter: Greater than 6 mm (standard pencil eraser).
E - Evolving: Dynamic change in size, shape, surface contour, elevation, or color, or new focal bleeding, itching, or crusting.
The "Ugly Duckling" Sign: A pigmented lesion that looks visibly distinct from all other nevi.
Biopsy Standards & Breslow Microstaging
Pregnancy is NEVER a contraindication to immediate biopsy ; local anesthesia with 1% lidocaine with epinephrine is safe.
Note
Mandatory Biopsy Technique: Perform a full-thickness excisional biopsy with 1 to 3 mm narrow margins into subcutaneous fat. Superficial shave biopsy is strictly contraindicated for suspicious pigmented lesions because it transects the base, compromising histological measurement of Breslow depth (vertical tumor thickness in millimeters). Breslow depth is the single most important prognostic indicator, dictating surgical margins, sentinel lymph node biopsy, and survival.